Neurocrine's 23% Slide Puts Ingrezza Raise And Crenessity Ramp Under The Microscope

Neurocrine Biosciences heads into its third-quarter report with one of the odder setups in large-cap biotech. Last quarter, management raised Ingrezza guidance for the first time this cycle, posted record revenue, lifted operating margins above 30% and closed the Soleno acquisition that added a third commercial franchise. The stock has since fallen 22.6%, trailing the S&P 500 by nearly 25 percentage points. When the company reports after the close on November 2, the question is whether the operating story has quietly cracked or whether the market has simply stopped paying for it.

Wall Street expects earnings of $2.57 per share on revenue of about $1.04 billion, a 30.8% jump from the $794.9 million booked a year ago and a solid step up from last quarter's $959 million. Much of that growth is mechanical, since this will be the first full quarter with Vykat XR on the books after the deal closed. On a pro forma basis, second-quarter revenue was already near $998 million, so the consensus implies only modest organic sequential progress. The Earnings Whisper of $2.49 sits a bit below consensus, which suggests the more skeptical corner of the market is braced for some noise on the bottom line, likely from elevated acquisition costs and expanded sales forces rather than weak demand.

Ingrezza remains the anchor. The new guidance range of $2.825 billion to $2.875 billion, up from $2.7 billion to $2.8 billion, combined with first-half sales of roughly $1.37 billion, implies the second half needs to average somewhere around $725 million to $750 million per quarter. Second-quarter sales of $716 million came with record new patient starts, so a third-quarter figure comfortably above that level, and ahead of the $687 million from a year ago, would validate the raise. A number that stalls near last quarter's pace would push the year toward the low end and invite questions about whether access pressure tied to Austedo XR's coming Medicare price negotiation is already biting.

Crenessity is the growth engine that most needs to keep compounding. Sales climbed from $98 million a year ago to $153 million in the first quarter and $184 million in the second, with penetration reaching about 15% of diagnosed patients and the prescriber base nearly tripling. Another meaningful sequential gain, ideally with penetration commentary moving higher, would support management's pitch that Neurocrine is no longer a single-product company. A flattening here would matter more than anything else in the release, because it would undercut the multi-driver thesis at exactly the moment investors are doubting it.

Vykat XR carries lower expectations by design. Management said sales of about $94 million were roughly flat as the company works through discontinuations from the 2025 launch bolus, and it only guided to sequential growth resuming in the fourth quarter. Flat is acceptable this time; a decline, or any sign that discontinuations are running above the 25% to 30% range management expects, would be a setback. Updates on integration costs, the cash balance after it dropped to roughly $500 million, and the open Justice Department inquiry into Ingrezza promotion will round out the picture.

Sentiment has drifted from mildly bullish before last quarter to mildly bearish now, and the shares sit at $142.70, below the 200-day moving average and closer to the post-earnings low of $132.25 than the $185.55 high. That leaves room for relief if the numbers hold up. Ultimately, the report hinges on whether Ingrezza tracks toward its raised guide while Crenessity keeps accelerating. If both happen, the selloff looks like a sentiment problem rather than a fundamental one.

This earnings preview was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.